These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31596672)

  • 1. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
    Narayan V; Puligandla M; Haas NB; Subramanian P; DiPaola RS; Uzzo R
    J Urol; 2019 Jan; 201(1):62-68. PubMed ID: 30130544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
    Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
    J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
    Jilaveanu LB; Puligandla M; Weiss SA; Wang XV; Zito C; Flaherty KT; Boeke M; Neumeister V; Camp RL; Adeniran A; Pins M; Manola J; DiPaola RS; Haas NB; Kluger HM
    Clin Cancer Res; 2018 Jan; 24(1):217-223. PubMed ID: 29066509
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
    Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
    Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
    Gharib KE
    Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
    Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
    Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
    Karam JA; Puligandla M; Flaherty KT; Uzzo RG; Matin SF; Pins MR; Wood CG; Kane C; Jewett MAS; Kim SE; Dutcher JP; DiPaola RS; Haas NB
    BJU Int; 2022 Jun; 129(6):718-722. PubMed ID: 34480522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
    Allaf ME; Kim SE; Master V; McDermott DF; Harshman LC; Cole SM; Drake CG; Signoretti S; Akgul M; Baniak N; Li-Ning E; Palmer MB; Emamekhoo H; Adra N; Kaimakliotis H; Ged Y; Pierorazio PM; Abel EJ; Bilen MA; Ogan K; Moon HH; Ramaswamy KA; Singer EA; Mayer TM; Lohrey J; Margulis V; Gills J; Delacroix SE; Waples MJ; James AC; Wang P; Choueiri T; Michaelson MD; Kapoor A; Heng DY; Shuch B; Leibovich BC; Lara PN; Manola J; Maskens D; Battle D; Uzzo R; Bratslavsky G; Haas NB; Carducci MA
    Lancet Oncol; 2024 Aug; 25(8):1038-1052. PubMed ID: 38942046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
    Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
    J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort.
    Jamil ML; Keeley J; Sood A; Dalela D; Arora S; Peabody JO; Trinh QD; Menon M; Rogers CG; Abdollah F
    Eur Urol; 2020 Feb; 77(2):277-281. PubMed ID: 31703971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
    Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
    Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
    Messing EM; Manola J; Wilding G; Propert K; Fleischmann J; Crawford ED; Pontes JE; Hahn R; Trump D;
    J Clin Oncol; 2003 Apr; 21(7):1214-22. PubMed ID: 12663707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
    Flaifel A; Xie W; Braun DA; Ficial M; Bakouny Z; Nassar AH; Jennings RB; Escudier B; George DJ; Motzer RJ; Morris MJ; Powles T; Wang E; Huang Y; Freeman GJ; Choueiri TK; Signoretti S
    Clin Cancer Res; 2019 Oct; 25(20):6080-6088. PubMed ID: 31371341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of renin is a prognostic factor for recurrence in nonmetastatic renal cell carcinoma.
    de Almeida E Paula F; Bezerra SM; da Cunha IW; Munhoz GC; Abreu D; Lara PN; da Costa WH; Zéqui SC
    Urol Oncol; 2019 Dec; 37(12):947-954. PubMed ID: 31473089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.
    Shah PH; Moreira DM; Patel VR; Gaunay G; George AK; Alom M; Kozel Z; Yaskiv O; Hall SJ; Schwartz MJ; Vira MA; Richstone L; Kavoussi LR
    J Urol; 2017 Aug; 198(2):289-296. PubMed ID: 28274620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
    Buti S; Puligandla M; Bersanelli M; DiPaola RS; Manola J; Taguchi S; Haas NB
    Ann Oncol; 2017 Nov; 28(11):2747-2753. PubMed ID: 28945839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
    Gross-Goupil M; Kwon TG; Eto M; Ye D; Miyake H; Seo SI; Byun SS; Lee JL; Master V; Jin J; DeBenedetto R; Linke R; Casey M; Rosbrook B; Lechuga M; Valota O; Grande E; Quinn DI
    Ann Oncol; 2018 Dec; 29(12):2371-2378. PubMed ID: 30346481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy for high-risk renal cell carcinoma patients.
    Kunkle DA; Haas NB; Uzzo RG
    Curr Urol Rep; 2007 Jan; 8(1):19-30. PubMed ID: 17239313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.